Evidence map›Paper›PMID 41142191›Full record

ArticleUrology case reports2025

Multidisciplinary therapy targeting histological heterogeneity in prostate cancer with bone marrow carcinomatosis: A case report.

Naoya Nagaya, Kento Hokota, Kaho Hirose, Junro Yanai, Junki Morino, Yuki Nagashima, Akiko Nakajima, Kazuhiko Fujita, Shigeo Horie

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naoya NagayaDepartment of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Kento HokotaDepartment of Urology, Juntendo Shizuoka Hospital, Shizuoka, Japan.
Kaho HiroseDepartment of Urology, Juntendo Shizuoka Hospital, Shizuoka, Japan.
Junro YanaiDepartment of Urology, Juntendo Shizuoka Hospital, Shizuoka, Japan.
Junki MorinoDepartment of Urology, Juntendo Shizuoka Hospital, Shizuoka, Japan.
Yuki NagashimaDepartment of Urology, Juntendo Shizuoka Hospital, Shizuoka, Japan.
Akiko NakajimaDepartment of Urology, Juntendo Shizuoka Hospital, Shizuoka, Japan.
Kazuhiko FujitaDepartment of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Shigeo HorieDepartment of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer with bone marrow carcinomatosis is rare and has a poor prognosis. A 68-year-old man with severe thrombocytopenia was diagnosed with prostate cancer based on MRI and bone marrow biopsy findings. Initial treatment with a GnRH antagonist and apalutamide showed limited efficacy for thrombocytopenia despite PSA response, prompting the addition of carboplatin and etoposide (CE) chemotherapy. Thrombocytopenia resolved following CE chemotherapy. After four CE cycles, ProGRP stabilized and PSA decreased significantly. Tumor control was maintained for a year with hormonal therapy. This case underscores the need for early, multidisciplinary treatment in histologically heterogeneous prostate cancer.

Identifiers

PMID41142191
PMCPMC12550340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.